условия использования материалов

Фармрынок / Pharm market

Практические рекомендации по лечению артериальной гипертензии во время пандемии COVID-19: обзор-2020

DOI: http://dx.doi.org/10.21518/1561-5936-2021-1-27-32

Алексей Водовозов, «Ремедиум»

Артериальная гипертензия (АГ) остается одной из важных глобальных проблем здоровья. Однако в 2020 г. она наложилась на не менее опасный вызов – COVID-19. Именно поэтому были выпущены обновленные рекомендации Международного общества гипертензии (ISH), в которых были собраны методы и препараты, лучше всего зарекомендовавшие себя в недавно проведенных рандомизированных контролируемых исследованиях. В некоторых аспектах они отличаются от вышедших ранее американских и европейских рекомендаций, например, в самом определении гипертензии, какое артериальное давление считать повышенным. Однако в плане медикаментозной терапии все три документа синхронны: необходимо начинать прием антигипертензивных средств как можно раньше и сразу же применять наиболее эффективные – ингибиторы ренин-ангиотензиновой системы (РАС) в сочетании с другими препаратами, подбираемыми индивидуально в зависимости от особенностей течения АГ у каждого конкретного пациента. Кроме того, выяснилось, что ингибиторы РАС позитивно влияют на течение COVID-19 у пациентов с АГ, что только увеличило актуальность мирового консенсуса по вопросу терапии АГ.

Practice guidelines for the treatment of arterial hypertension in the era of COVID-19: 2020 ISH global hypertension practice review

Alexey Vodovozov, Remedium

Arterial hypertension (AH) remains one of the most urgent global health challenges. However, it added up to an equally dangerous challenge – COVID-19 in 2020. That is why the International Society of Hypertension (ISH) released the updated guidelines comprising the methods and drugs that had proven themselves to be the best in the recent randomized controlled trials. In some respects, they differ from the previously issued American and European guidelines, for example, in the very definition for hypertension, which blood pressure threshold should be considered high. However, all three documents are synchronous in terms of drug therapy: it is necessary to start administering antihypertensive drugs as early as possible and immediately use the most effective ones – inhibitors of the renin-angiotensin system (RAS) combined with other drugs that are chosen individually depending on the features of the course of hypertension in each individual patient. In addition, it has been found that RAS inhibitors have a positive effect on the course of COVID-19 in patients with hypertension, which only increased the relevance of the global consensus on hypertension therapy.

Список литературы 

1. Hoffmann M., Kleine-Weber H., Schroeder S., Krüger N., Herrler T., Erichsen S. et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020;181(2):271–280.e8. doi: 10.1016/j.cell.2020.02.052. 

2. Guan W.J., Ni Z.Y., Hu Y., Liang W.H., Ou C.Q., He J.X. et al. linical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020;382(18):1708–1720. doi: 10.1056/NEJMoa2002032. 

3. Pranata R., Lim M.A., Huang I., Raharjo S.B., Lukito A.A. Hypertension is associated with increased mortality and severity of disease in COVID-19 pneumonia: A systematic review, metaanalysis and meta-regression. J Renin Angiotensin Aldosterone Syst. 2020;21(2):1470320320926899. doi: 10.1177/1470320320926899. 

4. Garg S., Kim L., Whitaker M., O’Halloran A., Cummings C., Holstein R. et al. Hospitalization Rates and Characteristics of Patients Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019 – COVID-NET, 14 States, March 1-30, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(15):458–464. doi: 10.15585/mmwr. mm6915e3.

5. Roncon L., Zuin M., Zuliani G., Rigatelli G. Patients with arterial hypertension and COVID-19 are at higher risk of ICU admission. Br J Anaesth. 2020;125(2):e254–e255. doi: 10.1016/j.bja.2020.04.056. 

6. Whelton P.K., Carey R.M., Aronow W.S., Casey D.E.Jr., Collins K.J. Dennison Himmelfarb C. et al. 2017 ACC/AHA/AAPA/ABC/ACPM/ AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2018;138(17):e426–e483. doi: 10.1161/CIR.0000000000000597. 

7. 2018 ESC/ESH Clinical Practice Guidelines for the Management of Arterial Hypertension. Available at: https://www.escardio.org/ Guidelines/Clinical-Practice-Guidelines/Arterial-HypertensionManagement-of (дата обращения 16.11.2020). 

8. Unger T., Borghi C., Charchar F., Khan N.A., Poulter N.R., Prabhakaran D. et al. 2020 International Society of Hypertension Global Hypertension Practice Guidelines. Hypertension. 2020;75(6):1334–1357. doi: 10.1161/HYPERTENSIONAHA.120.15026. 

9. Lewington S., Clarke R., Qizilbash N., Peto R., Collins R. Agespecific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies Lancet. 2002;360(9349):1903–1913. doi: 10.1016/ s0140-6736(02)11911-8. 

10. SPRINT Research Group, Wright J.T.Jr., Williamson J.D., Whelton P.K., Snyder J.K., Sink K.M., Rocco M.V. et al. A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med. 2015;373(22):2103–2116. doi: 10.1056/NEJMoa1511939/. 

11. Williams B., Mancia G., Spiering W., Agabiti Rosei E., Azizi M., Burnier M. et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021–3104. doi: 10.1093/eurheartj/ehy339. 

12. Fang J., Chang T., Wang G., Loustalot F. Association Between Cost-Related Medication Nonadherence and Hypertension Management Among US Adults. Am J Hypertens. 2020;33(9): 879–886. doi: 10.1093/ajh/hpaa072. 

13. Ferdinand D.P., Nedunchezhian S., Ferdinand K.C. Hypertension in African Americans: Advances in community outreach and public health approaches. Prog Cardiovasc Dis. 2020;63(1):40–45. doi: 10.1016/j.pcad.2019.12.005. 

14. Ostchega Y., Zhang G., Hughes J.P., Nwankwo T. Factors Associated With Hypertension Control in US Adults Using 2017 ACC/AHA Guidelines: National Health and Nutrition Examination Survey 1999- 2016. Am J Hypertens. 2018;31(8):886–894. doi: 10.1093/ajh/hpy047. 

15. Du L.P., Cheng Z.W., Zhang Y.X., Li Y., Mei D. The impact of fixed-dose combination versus free-equivalent combination therapies on adherence for hypertension: a meta-analysis. J Clin Hypertens (Greenwich). 2018;20(5):902–907. doi: 10.1111/jch.13272. 

16. Geldsetzer P., Manne-Goehler J., Marcus M.E., Ebert C., Zhumadilov Z., Wesseh C.S. et al. The state of hypertension care in 44 low-income and middle-income countries: a cross-sectional study of nationally representative individual-level data from 1·1 million adults. Lancet. 2019;394(10199):652–662. doi: 10.1016/S0140- 6736(19)30955-9. 

17. NCD Risk Factor Collaboration (NCD-RisC). Long-term and recent trends in hypertension awareness, treatment, and control in 12 high-income countries: an analysis of 123 nationally representative surveys. Lancet. 2019;394(10199):639–651. doi: 10.1016/S0140- 6736(19)31145-6. 

18. Lewington S., Clarke R., Qizilbash N., Peto R., Collins R. Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies Lancet. 2002;360(9349):1903–1913. doi: 10.1016/s0140-6736(02)11911-8. 

19. American Heart Association. Making an impact against COVID-19. Available at: https://www2.heart.org/site/DocServer/ Coronavirus_-_Making_an_Impact_Infographic_04.20. pdf?docID=6361 (дата обращения 16.11.2020). 

20. Kai H., Kai M. Interactions of coronaviruses with ACE2, angiotensin II, and RAS inhibitors-lessons from available evidence and insights into COVID-19. Hypertens Res. 2020;43(7):648–654. doi: 10.1038/s41440-020-0455-8. 

21. Reynolds H.R., Adhikari S., Pulgarin C., Troxel A.B., Iturrate E., Johnson S.B. et al. Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Covid-19. N Engl J Med. 2020;382(25):2441– 2448. doi: 10.1056/NEJMoa2008975. 

22. Yang G., Tan Z., Zhou L., Yang M., Peng L., Liu J. et al. Effects of Angiotensin II Receptor Blockers and ACE (Angiotensin-Converting Enzyme) Inhibitors on Virus Infection, Inflammatory Status, and Clinical Outcomes in Patients With COVID-19 and Hypertension: A Single-Center Retrospective Study. Hypertension. 2020;76(1):51–58. doi: 10.1161/HYPERTENSIONAHA.120.15143. 

23. Tedeschi S., Giannella M., Bartoletti M., Trapani F., Tadolini M., Borghi C., Viale P. Clinical Impact of Renin-angiotensin System Inhibitors on In-hospital Mortality of Patients With Hypertension Hospitalized for Coronavirus Disease 2019. Clin Infect Dis. 2020;71(15):899–901. doi: 10.1093/cid/ciaa492. 

24. Meng J., Xiao G., Zhang J., He X., Ou M., Bi J. et al. Reninangiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension. Emerg Microbes Infect. 2020;9(1):757–760. doi: 10.1080/22221751.2020.1746200. 

25. Khera A., Baum S.J., Gluckman T.J., Gulati M., Martin S.S., Michos E.D. et al. Continuity of care and outpatient management for patients with and at high risk for cardiovascular disease during the COVID-19 pandemic: A scientific statement from the American Society for Preventive Cardiology. Am J Prev Cardiol. 2020;1:100009. doi: 10.1016/j.ajpc.2020.100009. 

26. Vaduganathan M., Vardeny O., Michel T., McMurray J.J.V., Pfeffer M.A., Solomon S.D. Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19. N Engl J Med. 2020;382(17):1653–1659. doi: 10.1056/NEJMsr2005760. 

27. Solaimanzadeh I. Nifedipine and Amlodipine Are Associated With Improved Mortality and Decreased Risk for Intubation and Mechanical Ventilation in Elderly Patients Hospitalized for COVID-19. Cureus. 2020;12(5):e8069. Published 2020 May 12. doi: 10.7759/cureus.8069.

Ключевые слова: артериальная гипертензия, COVID-19, ISH, клинические рекомендации, ингибиторы АПФ, блокаторы ангиотензиновых рецепторов, блокаторы кальциевых каналов, тиазидоподобные диуретики, бета-блокаторы

Вернуться назад

Архив номеров
Archive of "Remedium"

2020   2019    2018   2017   2016  2015    2014    2013    2012   2011   2010   2009   2008   2007   2006  2005    2004   2003

© Remedium 2014-2021
Все права защищены